Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Scott

Allergy & Immunology Bessemer, AL Medical Doctor

NPI 1043247430 CMS profile 273835

975 9Th Ave Sw Ste 210, Bessemer, AL 35022

Open in the dashboard

General payments

$61,245

247 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,000 paid to institutions, not to them · program year 2021

Through program year 2025, Thomas Scott of Bessemer, AL is reported in the CMS Open Payments database as having received $61,245 across 247 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $160 2
2023 General $1,145 4
2022 General $525 17
2021 General $18,035 86
2020 General $9,504 53
2019 General $31,875 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Scott
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Thomas Scott were reported at $160. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Thomas Scott Allergy & Immunology median Middle half National median
2019 $31,875 $594 $163–$1,512 $163
2020 $9,504 $426 $106–$1,233 $114
2021 $18,035 $638 $157–$1,708 $132
2022 $525 $790 $205–$1,961 $149
2023 $1,145 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $160 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $32,315 39 payments
  2. GlaxoSmithKline, LLC. $23,933 63 payments
  3. AstraZeneca Pharmaceuticals LP $2,295 36 payments
  4. Pfizer Inc. $371 16 payments
  5. Celgene Corporation $273 3 payments
  6. OptiNose US, Inc. $254 21 payments
  7. ALK-Abello, Inc $253 4 payments
  8. Genzyme Corporation $187 5 payments
  9. CSL Behring $186 4 payments
  10. Genentech USA, Inc. $158 12 payments
  11. Other $1,019 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,075 25 payments
  2. Food and Beverage $6,178 208 payments
  3. Consulting Fee $1,163 1 payment
  4. Travel and Lodging $694 11 payments
  5. Honoraria $124 1 payment
  6. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. Enbrel Inflammation $18,984 22 payments
  2. NUCALA Respiratory $15,307 22 payments
  3. NUCALA Immunology $8,288 18 payments
  4. Enbrel Inflammation $2,503 3 payments
  5. Otezla $2,400 1 payment
  6. FASENRA $513 15 payments
  7. SYMBICORT $383 9 payments
  8. EUCRISA $314 13 payments
  9. TRELEGY ELLIPTA $313 21 payments
  10. SPIRIVA RESPIMAT $282 17 payments
  11. Other $3,318 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record